These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 22036941

  • 1. Cinacalcet HCl prevents development of parathyroid gland hyperplasia and reverses established parathyroid gland hyperplasia in a rodent model of CKD.
    Miller G, Davis J, Shatzen E, Colloton M, Martin D, Henley CM.
    Nephrol Dial Transplant; 2012 Jun; 27(6):2198-205. PubMed ID: 22036941
    [Abstract] [Full Text] [Related]

  • 2. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism.
    Colloton M, Shatzen E, Miller G, Stehman-Breen C, Wada M, Lacey D, Martin D.
    Kidney Int; 2005 Feb; 67(2):467-76. PubMed ID: 15673294
    [Abstract] [Full Text] [Related]

  • 3. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU.
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [Abstract] [Full Text] [Related]

  • 4. Cinacalcet upregulates calcium-sensing receptors of parathyroid glands in hemodialysis patients.
    Sumida K, Nakamura M, Ubara Y, Marui Y, Tanaka K, Takaichi K, Tomikawa S, Inoshita N, Ohashi K.
    Am J Nephrol; 2013 Jul; 37(5):405-12. PubMed ID: 23594726
    [Abstract] [Full Text] [Related]

  • 5. Evocalcet prevents ectopic calcification and parathyroid hyperplasia in rats with secondary hyperparathyroidism.
    Sakai M, Tokunaga S, Kawai M, Murai M, Kobayashi M, Kitayama T, Saeki S, Kawata T.
    PLoS One; 2020 Jul; 15(4):e0232428. PubMed ID: 32343734
    [Abstract] [Full Text] [Related]

  • 6. The calcimimetic AMG 641 abrogates parathyroid hyperplasia, bone and vascular calcification abnormalities in uremic rats.
    Henley C, Davis J, Miller G, Shatzen E, Cattley R, Li X, Martin D, Yao W, Lane N, Shalhoub V.
    Eur J Pharmacol; 2009 Aug 15; 616(1-3):306-13. PubMed ID: 19470383
    [Abstract] [Full Text] [Related]

  • 7. 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism.
    Henley C, Colloton M, Cattley RC, Shatzen E, Towler DA, Lacey D, Martin D.
    Nephrol Dial Transplant; 2005 Jul 15; 20(7):1370-7. PubMed ID: 15855208
    [Abstract] [Full Text] [Related]

  • 8. Cinacalcet HCl suppresses Cyclin D1 oncogene-derived parathyroid cell proliferation in a murine model for primary hyperparathyroidism.
    Imanishi Y, Kawata T, Kenko T, Wada M, Nagano N, Miki T, Arnold A, Inaba M.
    Calcif Tissue Int; 2011 Jul 15; 89(1):29-35. PubMed ID: 21541686
    [Abstract] [Full Text] [Related]

  • 9. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.
    Moe SM, Cunningham J, Bommer J, Adler S, Rosansky SJ, Urena-Torres P, Albizem MB, Guo MD, Zani VJ, Goodman WG, Sprague SM.
    Nephrol Dial Transplant; 2005 Oct 15; 20(10):2186-93. PubMed ID: 16030053
    [Abstract] [Full Text] [Related]

  • 10. Clinical experience with cinacalcet HCl.
    Ureña Torres P.
    Nephrol Dial Transplant; 2004 Aug 15; 19 Suppl 5():V27-33. PubMed ID: 15284357
    [Abstract] [Full Text] [Related]

  • 11. Histopathological alterations of the parathyroid glands in haemodialysis patients with secondary hyperparathyroidism refractory to cinacalcet hydrochloride.
    Sumida K, Nakamura M, Ubara Y, Marui Y, Tanaka K, Takaichi K, Tomikawa S, Inoshita N, Ohashi K.
    J Clin Pathol; 2011 Sep 15; 64(9):756-60. PubMed ID: 21565858
    [Abstract] [Full Text] [Related]

  • 12. Decreases in parathyroid gland volume after cinacalcet treatment in hemodialysis patients with secondary hyperparathyroidism.
    Ichii M, Ishimura E, Okuno S, Chou H, Kato Y, Tsuboniwa N, Nagasue K, Maekawa K, Yamakawa T, Inaba M, Nishizawa Y.
    Nephron Clin Pract; 2010 Sep 15; 115(3):c195-202. PubMed ID: 20413997
    [Abstract] [Full Text] [Related]

  • 13. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney disease.
    Quarles LD.
    Kidney Int Suppl; 2005 Jul 15; (96):S24-8. PubMed ID: 15954947
    [Abstract] [Full Text] [Related]

  • 14. Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism.
    Komaba H, Nakanishi S, Fujimori A, Tanaka M, Shin J, Shibuya K, Nishioka M, Hasegawa H, Kurosawa T, Fukagawa M.
    Clin J Am Soc Nephrol; 2010 Dec 15; 5(12):2305-14. PubMed ID: 20798251
    [Abstract] [Full Text] [Related]

  • 15. Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism.
    Meola M, Petrucci I, Barsotti G.
    Nephrol Dial Transplant; 2009 Mar 15; 24(3):982-9. PubMed ID: 19181759
    [Abstract] [Full Text] [Related]

  • 16. p21WAF1 and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium.
    Cozzolino M, Lu Y, Finch J, Slatopolsky E, Dusso AS.
    Kidney Int; 2001 Dec 15; 60(6):2109-17. PubMed ID: 11737585
    [Abstract] [Full Text] [Related]

  • 17. Direct in vitro evidence of the suppressive effect of cinacalcet HCl on parathyroid hormone secretion in human parathyroid cells with pathologically reduced calcium-sensing receptor levels.
    Kawata T, Imanishi Y, Kobayashi K, Onoda N, Okuno S, Takemoto Y, Komo T, Tahara H, Wada M, Nagano N, Ishimura E, Miki T, Ishikawa T, Inaba M, Nishizawa Y.
    J Bone Miner Metab; 2006 Dec 15; 24(4):300-6. PubMed ID: 16816924
    [Abstract] [Full Text] [Related]

  • 18. Does vitamin D receptor and calcium receptor activation therapy play a role in the histopathologic alterations of parathyroid glands in refractory uremic hyperparathyroidism?
    Lomonte C, Vernaglione L, Chimienti D, Bruno A, Cocola S, Teutonico A, Cazzato F, Basile C.
    Clin J Am Soc Nephrol; 2008 May 15; 3(3):794-9. PubMed ID: 18322048
    [Abstract] [Full Text] [Related]

  • 19. Can cinacalcet replace parathyroid intervention in severe secondary hyperparathyroidism?
    Kakuta T, Tanaka R, Kanai G, Sawaya A, Hirukawa T, Sato A, Saito A.
    Ther Apher Dial; 2009 Oct 15; 13 Suppl 1():S20-7. PubMed ID: 19765255
    [Abstract] [Full Text] [Related]

  • 20. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl.
    Nemeth EF, Heaton WH, Miller M, Fox J, Balandrin MF, Van Wagenen BC, Colloton M, Karbon W, Scherrer J, Shatzen E, Rishton G, Scully S, Qi M, Harris R, Lacey D, Martin D.
    J Pharmacol Exp Ther; 2004 Feb 15; 308(2):627-35. PubMed ID: 14593085
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.